U.S. markets open in 59 minutes
  • S&P Futures

    4,027.75
    -4.75 (-0.12%)
     
  • Dow Futures

    33,734.00
    -51.00 (-0.15%)
     
  • Nasdaq Futures

    11,936.25
    -31.75 (-0.27%)
     
  • Russell 2000 Futures

    1,894.40
    +0.90 (+0.05%)
     
  • Crude Oil

    77.39
    -0.51 (-0.65%)
     
  • Gold

    1,923.90
    -15.30 (-0.79%)
     
  • Silver

    23.38
    -0.36 (-1.51%)
     
  • EUR/USD

    1.0861
    +0.0005 (+0.04%)
     
  • 10-Yr Bond

    3.5510
    0.0000 (0.00%)
     
  • Vix

    20.22
    +1.71 (+9.24%)
     
  • GBP/USD

    1.2322
    -0.0032 (-0.26%)
     
  • USD/JPY

    130.0950
    -0.2630 (-0.20%)
     
  • BTC-USD

    22,921.82
    -197.67 (-0.85%)
     
  • CMC Crypto 200

    520.09
    -17.78 (-3.31%)
     
  • FTSE 100

    7,743.10
    -41.77 (-0.54%)
     
  • Nikkei 225

    27,327.11
    -106.29 (-0.39%)
     

Is This Biotech Stock a Buy Following a Landmark Approval?

Is This Biotech Stock a Buy Following a Landmark Approval?

Provention Bio (NASDAQ: PRVB) is a small-cap biotech whose shares have doubled in the past three months. The company can thank the expected and eventual approval of Tzield for that performance. In mid-November, Tzield became the first and only treatment approved by the U.S. Food and Drug Administration (FDA) for the delay of the onset of type 1 diabetes (T1D) in at-risk patients.